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Laboratory of Oncology, Istituto Giannina Gaslini, Genoa, ItalyBackground & Aims: Currently, staging of fibrosis in preclinical Lay summary: In response to damage and injury scars develop in
rodent liver fibrosis models is achieved histologically. Many ani- the liver and the main cell that makes the scar tissue is the hep-
mals are used at multiple time-points to assess disease progres-
sion or therapeutic responses. Hepatic myofibroblasts promote
liver fibrosis therefore quantifying these cells in vivo could assess
disease or predict therapeutic responses in mice. We fluores-
cently labelled a single chain antibody (C1-3) that binds hepatic
myofibroblasts to monitor fibrogenesis in vivo.
Methods: CCl4 was used to induce acute liver injury in WT and
cRel/ mice. Bile duct ligation was used to model chronic fibro-
sis. Hepatic myofibroblasts were depleted using a liposome-drug
delivery system or chemically with sulfasalazine. An IVIS
spectrum visualised fluorophore-conjugated C1-3 in vivo.
Results: IVIS detection of fluorescently labelled-C1-3 but not a
control antibody discriminates between fibrotic and non-
fibrotic liver in acute and chronic liver fibrosis models.
cRel/ mice have a fibro-protective phenotype and IVIS signal
is reduced in CCl4 injured cRel/ mice compared to wild-type.
In vivo imaging of fluorescently labelled-C1-3 successfully
predicts reductions in hepatic myofibroblast numbers in fibrotic
liver disease in response to therapy.
Conclusions:We report a novel fluorescence imaging method to
assess murine hepatic myofibroblast numbers in vivo during liver
fibrosis and after therapy. We also describe a novel liposomal
antibody targeting system to selectively deliver drugs to hepatic
myofibroblasts in vivo. C1-3 binds human hepatic myofibroblast
therefore imaging labelled-C1-3 could be used for clinical studies
in man to help stage fibrosis, demonstrate efficacy of drugs
that promote hepatic myofibroblast clearance or predict early
therapeutic responses.Journal of Hepatology 20
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to the scar forming HM. We have fluorescently labelled C1-3 and
given it to mice that have either normal or scarred livers (which
contain HM) and then used a machine called an in vivo imaging
system (IVIS) that takes pictures of different wavelengths of light,
to visualise the antibody binding to HM inside the living mouse.
Using fluorescently labelled C1-3 we can assess HM numbers in
the injured liver and monitor response to therapy. We have also
used C1-3 to target drugs encapsulated in lipid carriers (lipo-
somes) to the HM to kill the HM and reduce the liver disease.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Liver fibrosis is characterised by excess deposition of collagens by
the primary scar-producing cell in the liver the hepatic myofi-
broblast (HM) [1]. HM are generated from quiescent hepatic stel-
late cells (qHSC) upon injury via a process called activation [2]. In
acute liver injury HM produce a temporary scar to allow wound
healing and once the liver has regenerated and normal homeosta-
sis is restored, the HM are cleared by apoptosis or undergo
de-differentiation [3]. In chronic injury HM persist, migrate and
proliferate promoting scar formation and fibrosis [4,5]. Liver
fibrosis is a highly dynamic process that can either progress or
resolve. The HM is a key cell type regulating the kinetics of fibro-
sis and fibrolysis. HM accumulate during progression of liver
fibrosis but their clearance precedes fibrolysis and remodeling
of the scar matrix [6–8]. If a drug successfully treats the underly-
ing cause of injury, promotes HM apoptosis or if the injury
stimulus is removed the scar is remodeled [6,9].
Currently, histologically assessing fibrosis (Sirius Red) and HM
numbers (alpha-smooth muscle actin (aSMA)) in the liver is the
only accurate method to stage fibrosis in murine preclinical liver
fibrosis [5,10,11]. Therefore large numbers of animals are used for
multiple time-points to monitor disease kinetics or test novel
anti-fibrotic drugs. Developing a method to image and assess
HM in vivo would allow researchers to perform minimally inva-
sive longitudinal monitoring of fibrosis progression or resolution.
This could reduce the number of mice required to perform liver16 vol. 65 j 75–83
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disease models when comparing wild-type (WT) and transgenic
mice or predict early therapeutic responses when testing anti-
fibrotic drugs.
Synaptophysin mRNA is detected in rat quiescent hepatic stel-
late cells (qHSC) and cultured HM. Immuno-histochemical stain-
ing demonstrated co-localisation of synaptophysin and aSMA in
fibrotic liver [12]. C1-3-GT has previously been used to deplete
HM from the livers of acute and chronic carbon tetrachloride
(CCl4) injured mice [13], proving that C1-3 binds and successfully
delivers drugs to HM in vivo. However, this drug targeting
approach is limited by suitability of the drug in conjugation
chemistry. This study aims to exploit the HM binding properties
of C1-3 to develop two novel tools for fibrosis research. Firstly,
develop a novel imaging probe to monitor HM in vivo. Secondly,
conjugate C1-3 to liposomal carriers to selectively deliver drugs
to HM in vivo.Materials and methods
C1-3 Production and purification
pIMS-147-C1-3 plasmid transformed E-Coli XL-1 blue cells were cultured in Lyso-
geny broth media containing antibiotics (ampicillin and tetracycline). E-Coli
expressing pIMS-147-C1-3 were cultured in Luria-Bertani broth overnight then
in Terrific Broth media for 8 h. C1-3 expression was induced by adding isopropyl
b-D-1-thiogalactopyranoside to culture media for 4 h. Cells were lysed and C1-3
was purified from the supernatant using immobilised metal affinity chromatogra-
phy as previously described [13–15]. Endotoxin was removed using Q maxi H col-
umns (Sartorious Vivascience).
Liposomal preparation
C1-3 or CSBD9 coated sterically stabilised liposomes loaded with doxorubicin
were prepared as previously described [16]. Full details in Supplementary mate-
rials and methods.
Mice and models of liver injury
All experiments were performed on male C57BL/6 (WT) or global cRel knockout
mice (cRel/) mice under approval from the Newcastle Ethical Review Commit-
tee and a UK Home Office licence. Acute liver damage was induced by intraperi-
toneal injection of a single of dose of CCl4 at 2 ll/g body weight (CCl4:olive oil at
1:1 [vol/vol]). Bile duct ligation (BDL) was achieved by surgically exposing the
common bile duct followed by its double ligation. Appropriate pain relief was
given to all mice. Mice developed chronic liver fibrosis for a period of 14 days
[17].
Therapies
At 24 h post CCl4 injury animals were intravenously injected with C1-3 or CSBD9
coated sterically stabilised liposomes loaded with 5 mg/kg doxorubicin or empty
liposomes. Free doxorubicin was given at a concentration of 5 mg/kg. Chemical
depletion of HM was achieved by intraperitoneal injection of a single of dose sul-
fasalazine (150 mg/kg) 24 h post injury.
In vivo fluorescent imaging
Conjugation of C1-3 or CSBD9 to DyLight800 (Thermo Scientific) fluorophore was
performed following manufactures instruction. Sufficient quantities of C1-3 was
produced and labelled prior to each individual experiment to control for antibody
batch-to-batch variation or differences in labelling efficiency. Mice under isoflu-
rane were fluorescently imaged (745/800 em/ex filters) using epi-fluorescence on
an IVIS spectrum (Caliper Life Sciences) at 2 h, 4 h and 6 h post i.v. injection of
Dylight800 labelled-C1-3 for biodistribution studies. For all other experiments
the in vivo imaging of fluorescent labelled-C1-3 or CSBD9 was performed at 6 h
post C1-3/CSBD9 (10 mg/kg) administration. After the final scan mice were76 Journal of Hepatology 20humanely killed and the liver, kidney and spleen were excised and IVIS imaged
(745/800 em/ex filters). Images were analysed using Living Image 4.3.1 software,
regions of interest (ROI) were drawn as described in the Supplementary methods
section and average radiant efficiency [p/s/cm2/sr]/[lW/cm2] was calculated after
subtracting the background signal.
Statistical analysis
Data was analysed using Excel or GraphPad Prism, p values were calculated using
a two-tailed unpaired Student t test or one-way ANOVA with Newman-Kuels post
hoc test and p <0.05 (⁄), p <0.01 (⁄⁄) or p <0.001 (⁄⁄⁄) was considered significant.Results
We show that synaptophysin expression is increased in culture-
activated and in vivo activated mouse HM compared to qHSC
(Supplementary Fig. 1A–C). The single chain antibody (ScAb)
C1-3 recognises an extracellular domain in synaptophysin, a pro-
tein expressed on HM in the liver. C1-3 has been reported to bind
to HM but not qHSC or other liver cell types [12,14,15]. We show
binding of C1-3 to mouse and human HM in culture (Supplemen-
tary Fig. 1D) and report that the pro-apoptotic molecule gliotoxin
(GT) induces death (reduced cell attachment) of both quiescent
HSC and HM (Supplementary Fig. 1E–F). However, when GT is
conjugated to C1-3 (C1-3-GT) this complex is 25 fold less potent
at inducing death of qHSC (C) than HM (D), suggesting that C1-3
efficiently targets and kills HM.
CCl4 metabolism by the liver produces hepatotoxic free radi-
cals [14]. Administration of one dose of CCl4 to mice promotes
hepatocyte death and induces an inflammatory response, which
drives HM activation [18,19]. HM numbers peak between 48-
72 h with the majority of HM then cleared from the liver by
either apoptosis or de-differentiation by day 5 [20–22].
We wanted to establish the biodistribution and clearance
kinetics of C1-3 labelled with a near infra-red (NIR) fluorescent
dye (DyLight800) in mice with acute liver injury. 48 h acute
CCl4 injured WT C57/Bl6 mice were administered NIR
fluorophore-conjugated-C1-3 via the tail-vein followed by whole
body IVIS imaging at 2, 4, 6, 12 h, and 1 day. In vivo fluorescence
signal peaks at 2 h and then rapidly falls between 2-6 h. A further
decrease occurs between 6-12 h with the signal plateauing
between 12-24 h (Supplementary Fig. 2A). Ex vivo imaging of
organs at 48 h post CCl4 revealed that the fluorescence signal
was highest in the liver and little or no signal was detected in
the heart, spleen, pancreas or brain (Supplementary Fig. 2B). ScAb
are cleared by the kidneys and excreted into the urine [14,15]
therefore we expect to detect some fluorescence signal in the
ex vivo imaged kidney (Supplementary Fig. 2C). From the biodis-
tribution experiments we decided to image mice at 6 h for future
studies for three reasons: i) The majority of unbound antibody
has been excreted; ii) there is a strong signal from the liver; iii)
this time-point has the least mouse-to-mouse variation in fluo-
rescence signal (Supplementary Fig. 2A).
To verify that IVIS signal from fluorescently labelled C1-3 orig-
inates from the liver after injury we performed 2D fluorescence
imaging (Supplementary Fig. 3A–B) and Fluorescent Imaging
Tomography (FLIT) imaging (Fig. 1A), which uses geometry, depth
and intensity of the signal to build a 3D reconstruction of the
mouse and provide an anatomical localisation of the fluorescence
signal. 3D FLIT images show retention of fluorescently labelled-
C13 in the liver (Supplementary Movie 1), conversely, signal from
fluorescently labelled-CSBD9, a control ScAb predominantly16 vol. 65 j 75–83
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Fig. 1. Optical imaging of fluorescently labelled-C1-3 non-invasively monitors hepatic myofibroblasts in mice during acute liver injury. (A) Representative 2D IVIS
pictures of Fluorescent Imaging Tomography (FLIT) imaging of C1-3 or CSBD9 in 48 h CCl4 injured mice. (B) Whole body IVIS images of acute CCl4 and olive oil (oil) injured
mice. Red boxes show ROI. (C) Graph showing average radiant efficiency [p/s/cm2/sr]/[lW/cm2] of IVIS imaged mice. (D) Ex vivo images of liver, kidney and spleen. (E)
Graph showing average radiant efficiency. (F) Photomicrographs (3  3 fields, 100 magnification) of aSMA stained liver sections (scale bar, 200 l). (G) Graph showing
average aSMA+ area in CCl4 and oil injured mice. Data are means ± s.e.m, minimum n = 3/group. Unpaired t test, ⁄p <0.05 or ⁄⁄⁄p <0.001 compared to oil control.
JOURNAL OF HEPATOLOGYoriginates from the kidney with a low level of fluorescence
detected in the liver (Supplementary Movie 2). CSBD9 has an
identical antibody backbone to C1-3 but recognises a bacterial
protein and therefore should not bind mammalian proteins. Anal-
ysis of aSMA staining confirmed that the livers of C1-3 and
CSBD9 imaged mice contained similar numbers of HM (Supple-
mentary Fig. 3C).
To determine if IVIS imaging of fluorescently labelled-C1-3
could be used to monitor HM in vivo, we administrated
labelled-C1-3 intravenously to olive oil, vehicle treated mice or
acute CCl4 injured WT mice and then performed IVIS imaging.
Fluorescently labelled-C1-3 discriminates between normal (olive
oil) and acute CCl4 injured mice where HM are activated. Repre-
sentative IVIS images show a higher fluorescent signal from the
upper abdominal area where the liver is anatomically located in
acute CCl4 injured mice compared to olive oil control mice
(Fig. 1B). The average radiant efficiency was quantified by draw-
ing a ROI, denoted by red boxes (Fig. 1B), over the upper abdo-
men. Fig. 1C shows a highly significant increase in fluorescence
intensity in the CCl4 injured mice compared to olive oil mice.
To verify that the fluorescence signal originates from the liver
we removed the liver, kidney and spleen and performed ex vivo
imaging. The representative IVIS images and graph show that
the fluorescence intensity is significantly higher in livers of CCl4
injured mice than olive oil mice, with the signal being completely
lost in the olive oil group at 6 h post C1-3 administration
(Fig. 1D–E). As expected the histological levels of aSMA is signif-
icantly increased in the CCl4 injured mice compared to olive oil
mice (Fig. 1f–g). Liver injury in acute CCl4 treated mice was con-
firmed by elevation of the serum transaminases alanine transam-
inase (ALT) and aspartate aminotransferase (AST) compared to
the olive oil treated mice (Supplementary Table 1).
To exclude the possibility that there is non-specific retention
or non-specific hepatic clearance of the fluorescently labelled-C1-Journal of Hepatology 203 in the injured liver compared to the olive oil uninjured liver we
directly compared imaging of C1-3 with CSBD9 (control ScAb).
48 h CCl4 injured WT mice were given either fluorescently
labelled-C1-3 or CSBD9 and then IVIS imaged. We observe strong
fluorescence signal from the upper abdominal area of mice given
fluorescently labelled-C1-3 but no or low signal in the fluores-
cently labelled-CSBD9 group (Supplementary Fig. 4A). The differ-
ence in fluorescence signal is highly significant when quantified
as average radiant efficiency (Supplementary Fig. 4B). Ex vivo epi-
fluorescence imaging of the liver, kidney and spleen confirmed
that the fluorescence signal originated from the liver (Supple-
mentary Fig. 4C). A high liver signal is detected in the C1-3 group
and no signal is detected in the CSBD9 treated animals, ruling out
non-specific binding of the ScAb (Supplementary Fig. 4D). Serum
transaminases ALT and AST were elevated equally in both groups
of mice and the aSMA+ stained area in liver sections from the C1-
3 and CSBD9 imaged animals was similar, confirming that the
liver injury and HM activation was comparable in both groups
(Supplementary Table 1 and Supplementary Fig. 4E–F).
To ascertain if C1-3 imaging detects a therapeutic response in
acute liver injury we injured mice with CCl4 and then at 24 h,
once HM have activated we gave a single intraperitoneal dose
of sulfasalazine, a compound previously shown to induce HM
apoptosis in vitro and in vivo or phosphate buffered saline (PBS)
Veh control [23]. 24 h later mice were given fluorescently
labelled-C1-3 and IVIS imaged. The representative IVIS pictures
and average radiant efficiency graph show a statistically signifi-
cant reduction in epifluorescence in sulfasalazine treated mice
compared to the PBS control (Fig. 2A–B). Correlation analysis
shows a positive relationship (R2 = 0.70) between IVIS signal
and aSMA+ area (Supplementary Fig. 4G) between untreated
and sulfasalazine treated mice. The degree of liver injury quanti-
fied by increased ALT and AST levels was similar in both groups
(Supplementary Table 1) but HM numbers determined by hepatic16 vol. 65 j 75–83 77
ycneiciffetnaidar
gv
A
1.0
2.0
1.5
0.5
x1
08
Epifluorescence
PBS Sulf PBS Sulf
gvA
α
aera
%
+A
MS
PBSSulfSBP fluS
A B DC
*
4.0E+08
3.0E+08
2.0E+08
1.0E+08
0.0E+00
*
1.0
4.0
2.0
0.0
3.0
Fig. 2. Chemical depletion of hepatic myofibroblasts can be monitored in acute liver injury by C1-3. (A) Whole body IVIS images of acute CCl4 injured mice treated with
PBS vehicle or sulfasalazine (Sulf). Red boxes show ROI used to calculate the average radiant efficiency. (B) Graph showing Average Radiant Efficiency of PBS or sulfasalazine
treated acute CCl4 injured mice. (C) Photomicrographs at 100 magnification (3  3 fields) of aSMA stained liver sections. (D) Graph showing average aSMA+ stained area
in PBS or sulfasalazine treated acute CCl4 injured mice. (scale bar, 200 l). Data are means ± s.e.m, minimum n = 6/group. Unpaired t test, ⁄p <0.05 compared to PBS control.
Research ArticleaSMA+ staining from sulfasalazine treated mice was reduced by
50% compared to WT (Fig. 2C–D).
We previously reported that global cRel knockout mice
(cRel/), which lack the c-Rel subunit of the NF-jB transcription
factor family, are protected from developing liver fibrosis and
that fewer HM become activated in the liver of cRel/ mice dur-
ing acute or chronic liver injury [24]. To determine if our novel
imaging method is sensitive enough to detect differences in HM
activation between WT and transgenic mice we acute CCl4
injured WT and cRel/ mice and then performed IVIS imaging.WT cRel-/-
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ANOVA, ⁄p <0.05 or ⁄⁄⁄p <0.001 compared to WT.
78 Journal of Hepatology 20The in vivo epifluorescence signal was significantly increased in
WT mice compared with cRel/ mice (Fig. 3A–B) despite no dif-
ference in liver transaminases (Supplementary Table 1). Correla-
tion analysis revealed a strong relationship (R2 = 0.88) between
IVIS signal and aSMA+ area (Supplementary Fig. 4H), between
olive oil treated WT mice and acute CCl4 injured WT and cRel/
mice. Ex vivo imaging of the liver, kidney and spleen proved that
the fluorescence signal originated from the liver (Fig. 3C–D). As
expected there was a significant reduction in aSMA+ HM in the
livers of cRel/ mice compared to WT (Fig. 3E–F) confirming thatOil
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the IVIS signal correlated with HM numbers. When both strains
of injured mice were compared to olive oil controls, there was
an incremental increase in both in vivo and ex vivo IVIS signal
between olive oil, cRel/ and WT mice as HM increase
(Fig. 3A–F).
Taken together these data suggest that C1-3 can be used to
non-invasively image HM in vivo during acute liver injury, predict
a successful therapeutic response of an anti-fibrotic compound
and screen transgenic mice for fibro-protective phenotypes. We
next wanted to ask; can C1-3 monitor HM accumulation and pro-
gression of fibrosis in chronic liver injury?
BDL is a progressive liver fibrosis model [17,25]. We per-
formed BDL or a sham operation and then gave fluorescently
labelled-C1-3 or CSBD9 and IVIS imaged mice at day 3, day 7
and day 14. IVIS images show a significant increase in epifluores-
cence signal in C1-3 imaged BDL mice as disease progresses from
early (day 3), established (day 7) and advanced (day 14) fibrosis.
Conversely no or low signal was detected in the CSBD9 imaged
BDL mice or in the sham operated mice given either labelled
C1-3 or CSBD9 (Fig. 4A). The low level of fluorescence signal in
the CSBD9 group is likely due to slightly altered clearance2.5
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Journal of Hepatology 20kinetics in chronic injured mice and/or due to physiological dif-
ferences between the BDL and acute CCl4 models. Serum
transaminases, ALT, AST and alkaline phosphatase (ALP) a marker
of biliary damage and the number of CK19+ biliary cells were
similar between BDL mice imaged with C1-3 and CSBD9 at each
time-point suggesting that there was no difference in liver injury
or ductular reaction between the two groups as the model pro-
gressed (Supplementary Table 1 and Supplementary Fig. 5A). IVIS
signal is statistically significantly different between BDL mice
imaged with C1-3 and CSBD9 at all time-points or when C1-3
BDL mice are compared to sham operated animals (Fig. 4B). How-
ever, there are no differences in fluorescence intensity between
sham operated control mice and the CSBD9 imaged BDL mice.
HM numbers and fibrosis severity were histologically
assessed using aSMA immuno-histochemistry and Sirius Red
staining. aSMA+ area was similar at each time-point between
C1-3 and CSBD9 imaged mice, therefore the reduction in fluores-
cence signal in the CSBD9 imaged BDL group is not due to fewer
HM (Fig. 4C-D). HM were present by day 3 and numbers signifi-
cantly increased at day 7 but plateaued by day 14, interestingly
there was no difference in IVIS signal in C1-3 imaged mice fromB
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day 7 to day 14, suggesting that the epifluorescence accurately
predicted the number of HM in the liver. Indeed, correlative anal-
ysis of average radiant efficiency vs. aSMA+ area shows positive
correlation (R2 = 0.79) in fluorescence signal between sham ani-
mals and BDL mice (Supplementary Fig. 5B). Fibrotic scar matrix
steadily accumulates from day 3 to day 14 and there are no dif-
ferences in Sirius Red stained area between C1-3 and CSBD9
imaged BDL mice (Fig. 4E–F). Fluorescence signal correlates
poorly with collagen (R2 = 0.29) providing additional evidence
that C1-3 selectively binds HM and does not non-specifically bind
to collagen matrix (Supplementary Fig. 5C).
Global cRel gene knockout mice or systemic administration of
sulfasalazine reduces HM numbers in the injured liver. However,
these HM depleting approaches are not selective and may have
unexpected affects on IVIS imaging. We therefore wanted to test
whether C1-3 imaging can monitor targeted depletion of HM
from injured livers of WT mice. Liposomes provide a unique sys-
tem to encapsulate drugs and when complexed to targeting
molecules e.g., an antibody or receptor ligand can selectively deli-
ver therapeutic agents to specific cells or organs in vivo
[16,26,27]. Therefore targeted liposomal drug delivery can
improve efficacy and reduce side effects. Doxorubicin therapy
reduces fibrosis in BDL injured rats [28]. However, this drug has48 h 72 h Day 5
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80 Journal of Hepatology 20cytotoxic effects at high concentrations. A single dose of 5 mg/
kg free doxorubicin in acute CCl4 injury caused a modest but
insignificant increase in serum liver enzymes and a small but
insignificant reduction in aSMA+ area (Supplementary Fig. 6A–
B). To selectively deplete HM in vivo during acute liver injury
we have exploited the HM binding properties of C1-3 and devel-
oped a new method to target liposomes encapsulating 5 mg/kg
doxorubicin to HM. C1-3-coated liposomes but not uncoated
liposomes (control) bind to mouse and human HM in culture
but primary hepatocytes or the Raji B cell line (Supplementary
Fig. 6C). Mice were injured with CCl4 and then given
C1-3-Doxorubin-liposomes (C1-3-Lipo-DOX) or C1-3-empty-
liposomes (control) 24 h later. Liver and blood samples were then
harvested at 48 h, 72 h and 5 days post CCl4. Liver enzymes ALT,
AST and ALP were elevated equally in both groups suggesting
that DOX liposomes did not exacerbate liver injury (Supplemen-
tary Table 1). aSMA+ area was significantly reduced at all time-
points in the C1-3-Lipo-DOX treated animals compared to the
control liposomes, confirming that this method depletes HM
in vivo in acute liver injury (Fig. 5A–B). As expected, hepatic
expression of the pro-fibrotic genes collagen I, aSMA, TIMP1
and TGFb1 were significantly decreased at 72 h in mice that
received Lipo-DOX (Fig. 5C). Importantly, C1-3-Lipo-DOX didDay 5
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not affect the inflammatory response to acute liver injury with
neutrophil (NIMP-R14) and T-lymphocyte (CD3) recruitment
and macrophage (F4/80) numbers being similar between both
groups (Supplementary Fig. 6D–E). This was consistent with no
difference in hepatic expression of the inflammatory genes TNFa,
IL-1b, KC and MCP1 in control or DOX liposome treated mice
(Fig. 5D). HM have been reported to suppress liver regeneration
after injury [29]. Interestingly, at day 5 the DOX treated mice
have a significantly higher proliferative rate than mice treated
with control liposomes (Supplementary Fig. 6G). These data
prove that C1-3-liposomes can be used to deliver apoptosis-
inducing drugs to HM and promote their clearance in vivo. We
next repeated this study and performed IVIS imaging to prove
that fluorescently labelled-C1-3 can monitor targeted depletion
of HM. 24 h post CCl4 injury mice were given vehicle control,
empty liposome (Empty-Lipo) control, uncoated liposomes con-
taining DOX (Lipo-DOX) control or C1-3 coated liposomes encap-
sulating DOX to specifically target and deplete HM (C1-3-Lipo-
DOX) followed by IVIS imaging 48 h later. Both in vivo and
ex vivo imaging revealed that the fluorescent C1-3 IVIS signal
was only reduced in the C1-3-Lipo-DOX group (Supplementary
Fig. 7A–B). HM depletion in mice receiving C1-3-Lipo-DOX was
confirmed by a reduction in aSMA+ area (Supplementary
Fig. 7C) and there was a positive correlation between aSMA+ area
and C1-3 IVIS signal, R2 = 0.77 (Supplementary Fig. 7D). Serum
transaminases were elevated equally in all groups (Supplemen-
tary Table 1).
Finally, we compared imaging fluorescently labelled-C1-3
after administration of C1-3-Lipo-DOX or DOX containing lipo-
somes coated with the control ScAb CSBD9 (CSBD9-Lipo-DOX).
Mice were CCl4 injured and then at 24 h were given C1-3-Lipo-
DOX to deplete HM or CSBD9-lipo-DOX non-targeting, control
liposomes. Mice were then given fluorescently labelled-C1-3 at
72 h post CCl4 and then IVIS imaged 6 h later. Data in Fig. 6A–B0.6
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Journal of Hepatology 20show a clear reduction in IVIS signal in the C1-3-Lipo-DOX trea-
ted mice, where HM are selectively depleted compared to the
CSBD9-Lipo-DOX group. This imaging approach can be used to
monitor selective depletion of HM by C1-3-Lipo-DOX. However,
it is important to consider that C1-3 is both targeting liposomes
to HM to induce their apoptosis as well as monitor HM numbers;
therefore we cannot exclude the possibility some of the reduction
in signal in this experiment may be due to internalisation or
blocking of synaptophysin by C1-3-Lipo-DOX. Ex vivo imaging
of organs confirmed that the fluorescent signal is restricted to
the liver and is higher in the CSBD9-Lipo-DOX group (Fig. 6C–D).
HM depletion in mice receiving C1-3-Lipo-DOX was confirmed
by a reduction in aSMA+ area (Fig. 6E–F). Serum transaminases
were elevated equally between both groups confirming that the
liver injury was similar (Supplementary Table 1).Discussion
Molecular optical imaging of fluorescent probes for in vivo stud-
ies permits non-invasive longitudinal assessment of biological
processes and uses fewer animals compared to traditional pre-
clinical models where multiple time-points are needed to evalu-
ate disease progression or assess therapeutic effects. This
technology provides insight into disease pathogenesis; however,
there are limitations and technical hurdles that need to be over-
come when developing a new fluorescence-based imaging
method [30,31]. In whole animals, in vivo fluorescence imaging
is limited by tissue thickness, auto-fluorescence quenching and
light scattering, making visualisation of deep-seated organs such
as the liver challenging [32]. C57Bl/6 mice are often the preferred
strain for preclinical mouse models because the majority of
transgenic mice are generated on this background. However, flu-
orescent imaging of C57Bl/6 mice is difficult, black skin and furEpifluorescence
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absorbs light causing signal attenuation resulting in lower signal
to noise ratio. Shaving mice can alleviate this problem but shav-
ing disrupts the hair growth cycle causing increased melanin
deposition and dark skin pigmentation [33]. Using different
strains e.g., white haired BALB/c mice or imaging C57Bl/6 mice
with NIR probes, which reduce signal attenuation and scattering,
can help overcome this problem.
We used an 800 nm protein labelling kit to conjugate a NIR
fluorophore to C1-3 to monitor HM numbers in C57Bl/6 mice
with liver fibrosis, highlighting the potential of this technology
as a non-invasive imaging tool. NIR protein conjugation kits are
commercially available; therefore in vivo fluorescence molecular
imaging is potentially only limited by the identification of a tar-
get and availability of an antibody, ligand or peptide that binds
the target. As such, this imaging strategy could be applied to
other animal disease models. It is important to note that labelling
efficiency of the fluorescent dye to the antibody can vary
between labelling reactions. To minimise any potential variation
in longitudinal studies and compare average radiant efficiency
and HM numbers we have synthesised and labelled large quanti-
ties of antibodies in a single batch. Whilst absolute quantification
of HM numbers in the injured liver by IVIS imaging is not achiev-
able, this technology allows researchers to monitor stepwise
changes in relative HM numbers within the same animal over
the course of liver disease development. Furthermore, the
changes in HM numbers can be directly compared between
several experimental groups of animals within the same
experiment.
We report for the first time that optical imaging of fluores-
cently labelled-C1-3 successfully monitors HM numbers in acute
and chronic liver fibrosis models in C57Bl6 mice in vivo. IVIS
imaging of acute injured WT and cRel/ mice that develop less
fibrosis demonstrated that this molecular imaging approach
identifies mice with fibro-protective phenotypes. Therefore, this
imaging method could be used to screen and identify genetically
modified mice, which are more or less susceptible to developing
fibrosis without needing to confirm this histologically. Further-
more, we prove that this technology can monitor early response
to therapies, which induce HM apoptosis or limit their activation/
proliferation.
C1-3 mediated targeting of liposomes to HM could be
exploited to deliver other payloads such as novel anti-fibrotic
compounds that induce HM death or modulate their phenotype.
Directly targeting drugs to HM to limit fibrosis in vivo without
affecting other cell types is likely to improve drug efficacy and
reduce side effects. Alternatively, C1-3-targeted-liposomes could
be used to deliver siRNA or anti-sense oligonucleotides to selec-
tively knockdown expression of fibrogenic regulators in HM in
a temporal manner e.g. once fibrosis is established. This would
help address the role of these genes/proteins in HM during fibro-
genesis without the need to use costly and time-consuming
genetic mouse models that rely on Cre deleter-mice to selectively
remove the gene in HM.
In vivo fluorescent imaging is high throughput (5 animals/
scan) and cost effective compared to other imaging modalities.
We suggest that molecular imaging of HM using fluorescently
labelled-C1-3 could be a useful tool for proof-of-concept studies
or drug discovery studies where large numbers of compounds/-
doses are screened for a therapeutic effect or where an early
predictor of therapeutic response is needed. In vivo imaging is
now utilised as a translational vehicle between preclinical and82 Journal of Hepatology 20early clinical studies. Recent advances in optical imaging cam-
eras, narrower bandwidth filters and spectral un-mixing algo-
rithms have improved IVIS sensitivity and the resolution is
closer to positron emission tomography (PET) and single photon
emission computed tomography (SPECT) [30–32]. In man liver
biopsy is the gold standard procedure for the diagnosis and stag-
ing of liver fibrosis. However, liver biopsy has been criticised for
its lack of reproducibility, interobserver and intraobserver vari-
ability and patient intolerability.
C1-3 binds to human HM, therefore C1-3 has the potential to
be translated to man and used as an in vivo diagnostic agent
when combined with clinically translatable imaging modalities
such as PET or SPECT. Clinical imaging of C1-3 either alone or
with existing serum fibrosis markers could be employed to help
identify patients with progressive disease or predict an early
effective therapy in clinical trials. Alternatively, C1-3 could be
engineered to selectively deliver drugs to HM, which would
reduce off-target adverse effects caused by a systematic adminis-
tration of the drug, or improve compound efficacy.Financial support
This work was funded by the UK Medical Research Council (MRC)
(Grant MR/K0019494/1 to D.A.M and G0900535 to F.O.). A Euro-
pean Commission FP7 grant ‘INFLA-CARE’ (EC Contract No.
223151; http://inflacare.imbb.forth.gr/) to D.A.M, M.P. and
others. D.A.M and F.O are funded by the cross-council Lifelong
Health and Wellbeing initiative, which is managed by the MRC
(award reference i L016354). HM was funded by the Hunter
Memorial Fund. Partially supported by AIRC IG 2012 Grant
IG12994 to P.P. and AIRC 2013 Grant IG14231 to M.P, D.D.P. par-
tially supported by award from Fondazione Umberto Veronesi.
The IVIS spectrum was purchased under a Wellcome Trust Equip-
ment Grant (087961) awarded to D.A.M and others.Conflict of interest
M.C.W. has a financial interest in any commercial exploitation of
the C1-3 antibody through any licensing agreement of a previous
employer but takes no part and has no influence on any commer-
cialisation activities. All other authors declared that they do not
have anything to disclose regarding funding or conflict of interest
with respect to this manuscript.Authors’ contributions
S.L. performed the majority of the laboratory-based work and
analyses presented in the manuscript. S.J.H, J.L, H.L.M and H.B.
performed a portion of the laboratory experiments and their
related analyses. D.D.P, P.P, C.B and M.P generated and provided
liposomes. M.C.W, M.P and D.A.M., provided advice and con-
tributed to the experimental design. S.L and F.O. conceived the
studies, designed the experiments and wrote the manuscript.
All authors read and commented on the final manuscript.Supplementary data
Supplementarydataassociatedwiththisarticlecanbe found, in the
online version, at http://dx.doi.org/10.1016/j.jhep.2016.03.021.16 vol. 65 j 75–83
JOURNAL OF HEPATOLOGY
References
[1] Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel
insights into liver fibrosis. Am J Physiol Cell Physiol 2013;305:C789–C799.
[2] Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and
repair: immune regulation of wound healing in a solid organ. Nat Rev
Immunol 2014;14:181–194.
[3] Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic
stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005;10:
927–939.
[4] Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate
tracing reveals hepatic stellate cells as dominant contributors to liver
fibrosis independent of its aetiology. Nat Commun 2013;4:2823.
[5] Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin
of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A
2014;111:E3297–E3305.
[6] Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a transla-
tional success story. Gut 2015;64:830–841.
[7] Barcena C, Stefanovic M, Tutusaus A, Joannas L, Menendez A, Garcia-Ruiz C,
et al. Gas6/Axl pathway is activated in chronic liver disease and its targeting
reduces fibrosis via hepatic stellate cell inactivation. J Hepatol 2015;63:
670–678.
[8] Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al.
Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate
cell apoptosis and reduced hepatic expression of metalloproteinase
inhibitors. J Clin Invest 1998;102:538–549.
[9] Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin
stimulates the apoptosis of human and rat hepatic stellate cells and
enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;
121:685–698.
[10] Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse
model of carbon tetrachloride induced liver fibrosis: histopathological
changes and expression of CD133 and epidermal growth factor. BMC
Gastroenterol 2010;10:79.
[11] Liu Y, Lui EL, Friedman SL, Li L, Ye T, Chen Y, et al. PTK787/ZK22258
attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting
VEGF signaling. Lab Invest 2009;89:209–221.
[12] Cassiman D, van Pelt J, De Vos R, Van Lommel F, Desmet V, Yap SH, et al.
Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J
Pathol 1999;155:1831–1839.
[13] Douglass A, Wallace K, Parr R, Park J, Durward E, Broadbent I, et al. Antibody-
targeted myofibroblast apoptosis reduces fibrosis during sustained liver
injury. J Hepatol 2008;49:88–98.
[14] Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC. Targeting
liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol
Int 2008;2:405–415.
[15] Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, et al.
Generation of a monoclonal human single chain antibody fragment to
hepatic stellate cells–a potential mechanism for targeting liver anti-fibrotic
therapeutics. J Hepatol 2005;42:888–896.
[16] Di Paolo D, Loi M, Pastorino F, Brignole C, Marimpietri D, Becherini P, et al.
Liposome-mediated therapy of neuroblastoma. Methods Enzymol 2009;465:
225–249.Journal of Hepatology 20[17] Perugorria MJ, Murphy LB, Fullard N, Chakraborty JB, Vyrla D, Wilson CL,
et al. Tumor progression locus 2/Cot is required for activation of extracel-
lular regulated kinase in liver injury and toll-like receptor-induced TIMP-1
gene transcription in hepatic stellate cells in mice. Hepatology 2013;57:
1238–1249.
[18] Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of
haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol
2003;33:105–136.
[19] Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411:1–18.
[20] Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD,
et al. Spontaneous recovery from micronodular cirrhosis: evidence for
incomplete resolution associated with matrix cross-linking. Gastroenterol-
ogy 2004;126:1795–1808.
[21] Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role
of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology
2001;34:89–100.
[22] Troeger JS, Mederacke I, Gwak GY, Dapito DH, Mu X, Hsu CC, et al.
Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.
Gastroenterology 2012;143 e1022.
[23] Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, et al. Inhibition of
inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and
accelerated recovery from rat liver fibrosis. Gastroenterology 2005;128:
108–120.
[24] Gieling RG, Elsharkawy AM, Caamano JH, Cowie DE, Wright MC, Ebrahim-
khani MR, et al. The c-Rel subunit of nuclear factor-kappaB regulates murine
liver inflammation, wound-healing, and hepatocyte proliferation. Hepatol-
ogy 2010;51:922–931.
[25] Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH,
Tacke F, et al. Bile duct ligation in mice: induction of inflammatory liver
injury and fibrosis by obstructive cholestasis. J Vis Exp 2015(96):52438.
[26] Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to
clinical applications. Adv Drug Deliv Rev 2013;65:36–48.
[27] Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of
liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a
collagen-specific chaperone. Nat Biotechnol 2008;26:431–442.
[28] Greupink R, Bakker HI, Bouma W, Reker-Smit C, Meijer DK, Beljaars L, et al.
The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-
ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J
Pharmacol Exp Ther 2006;317:514–521.
[29] Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ,
et al. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B
receptor in chronic liver disease. Nat Med 2011;17:1668–1673.
[30] Hassan M, Klaunberg BA. Biomedical applications of fluorescence imaging
in vivo. Comp Med 2004;54:635–644.
[31] Bremer C, Ntziachristos V, Weissleder R. Optical-based molecular imaging:
contrast agents and potential medical applications. Eur Radiol 2003;13:
231–243.
[32] Hickson J. In vivo optical imaging: preclinical applications and considera-
tions. Urol Oncol 2009;27:295–297.
[33] Curtis A, Calabro K, Galarneau JR, Bigio IJ, Krucker T. Temporal variations of
skin pigmentation in C57BL/6 mice affect optical bioluminescence quanti-
tation. Mol Imaging Biol 2011;13:1114–1123.16 vol. 65 j 75–83 83
